奥曲肽联合埃索美拉唑对重症胰腺炎患者临床疗效及血清CRP、TNF-α、IL-6水平的影响

Effect of Octreotide Combined with Esomeprazole on Clinical Efficacy and Serum CRP,TNF-αand IL-6 Levels in Patients with Severe Pancreatitis

目的:探讨奥曲肽联合埃索美拉唑对重症胰腺炎患者临床疗效及血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)与白介素-6(IL-6)水平的影响。方法:选取2018年2月-2020年2月本院收治的60例重症胰腺炎患者,按随机数字表法分为对照组与研究组,每组30例。对照组应用奥曲肽治疗,研究组在对照组基础上联合埃索美拉唑治疗。比较两组治疗效果、症状恢复时间、治疗前后腹内压、急性生理与慢性健康状况评分Ⅱ(APACHEⅡ)评分、尿淀粉酶、血清淀粉酶及生活质量评分。结果:研究组治疗总有效率高于对照组(P<0.05)。研究组各症状恢复时间均短于对照组(P<0.05)。治疗后,研究组腹内压、APACHEⅡ评分、尿淀粉酶与血清淀粉酶均低于对照组(P<0.05)。治疗后,研究组IL-6、TNF-α及CRP水平均低于对照组(P<0.05)。治疗后,研究组各生活质量评分均高于对照组(P<0.05)。结论:奥曲肽联合埃索美拉唑治疗重症胰腺炎效果显著,可改善患者的临床症状,恢复尿淀粉酶与血清淀粉酶正常水平,降低腹内压和炎症反应,提高生活质量,值得临床推广。

Objective:To investigate the effect of Octreotide combined with Esomeprazole on serum c-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)levels in patients with severe pancreatitis.Method:A total of 60 patients with severe pancreatitis admitted to our hospital from February 2018 to February 2020 were selected.They were divided into control group and study group according to the random number table method,30 patients in each group.The control group was treated with Octreotide,and the study group was treated with Esomeprazole on the basis of the control group.The treatment effect,symptom recovery time,intra-abdominal pressure,acute physiology and chronic health evaluation scoring systemⅡ(APACHEⅡ),urinary amylase,serum amylase and quality of life scores before and after treatment were compared between two groups.Result:The total effective rate of the study group was higher than that of the control group(P<0.05).The recovery time of each symptom in the study group were shorter than those of the control group(P<0.05).After treatment,the intra-abdominal pressure,APACHEⅡscore,urinary amylase and serum amylase in the study group were lower than those in the control group(P<0.05).After treatment,the levels of IL-6,TNF-αand CRP in the study group were lower than those in the control group(P<0.05).After treatment,the all quality of life scores in the study group were higher than those in the control group(P<0.05).Conclusion:Octreotide combined with Esomeprazole has a significant effect in the treatment of patients with severe pancreatitis,which can improve the clinical symptoms of patients,restore the normal levels of urinary amylase and serum amylase,reduce abdominal pressure and inflammatory response,and improve the quality of life,it is worthy of clinical promotion.